The AI engine is offline (last seen Aug 12, 05:02 UTC). Scores are shown as of their timestamps; new theses and refreshes are queued and run the moment it returns.

Macro

Search catalysts, news stories, and pressures, or browse the trust-weighted news feed below.

Home tech energy finance healthcare defense industrial consumer communication utilities real estate raw materials
← back
healthcare · sector mood
2000
year mood +0.40 · +0.30 to +0.57 across 12 mo
Monthly mood
bearish −1 +1 bullish
-0.75 -0.38 0 +0.38 +0.75 Jan Feb +0.57 Mar Apr +0.30 May Jun Jul Aug Sep Oct Nov Dec
month values ▾
JanFebMarAprMayJunJulAugSepOctNovDec
+0.48+0.57+0.40+0.30+0.30+0.30+0.40+0.40+0.40+0.40+0.40+0.40

Healthcare sentiment is positive this month, driven primarily by Pfizer’s $90 billion acquisition of Warner-Lambert, a major consolidation move that underscores confidence in pipeline integration and cost synergies. This deal sets a precedent for strategic scaling within the pharmaceutical segment, amplifying sector-wide optimism. The broader backdrop of stable regulatory conditions supports continued M&A momentum.

How this mood is scored ▾
Each day the model reads that day's news for the sector and asks, as someone who owns assets or makes their living in it: how am I feeling this month, and why? The month's mood is that running answer, tied to the specific events driving it (the story shown above). It leans on trusted, higher-impact reporting, and on the prior month when a month is quiet, so one loud headline can't swing it. The read updates daily through the month; once a month ends, its mood is locked. This year is read live from the news the pipeline actually collected (hover a bar for its story count). · last computed Jul 06, 2026
Top healthcare stories of 2000
Jan
Glaxo and SmithKline to merge in $76B pharma deal cbsnews.com →

Glaxo Wellcome and SmithKline Beecham agreed to merge, forming the world's largest pharmaceutical company with $17.8 billion in annual sales and a 7.3% global market share. The $76 billion deal, pending regulatory approval, aims for $1.6 billion in cost savings and will likely spur further industry consolidation. The merger highlights strategic pressures in Big Pharma to scale up R&D and marketing amid rising drug development costs.

Feb
Pfizer acquires Warner-Lambert for $90 billion in industry consolidation cbc.ca →

Pfizer has won a three-month bidding war to acquire Warner-Lambert for $90 billion, creating the world's second-largest pharmaceutical company. The deal, which includes a $1.8 billion breakup fee to American Home Products, unites two major drugmakers behind key products like Lipitor and Listerine. This merger accelerates consolidation in the pharmaceutical sector, following Glaxo Wellcome and SmithKline Beecham's recent merger, with significant implications for market competition and R&D scale.